Effects of Modulator Therapy on Cystic Fibrosis Microbiome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate how Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy affects the microbiome and inflammation in the paranasal sinuses of adults with cystic fibrosis. Participants will provide nasal samples, undergo olfactory function testing, and complete surveys regarding their quality of life and sense of smell over a two-year period with five research visits. The study will analyze bacterial communities and inflammatory profiles to understand the therapy's impact on sinonasal disease and overall health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects between the ages of 18 years old (inclusive) and 99 years old (inclusive)
* English-speaking
* Diagnosed with CF as established by genetic testing combined with clinical assessment and/or sweat chloride
* Patients being seen at the New Hampshire Cystic Fibrosis Center
* Adults able to sign informed consent

Exclusion Criteria:

* Adults unable to consent
* Individuals who are not yet adults
* Prisoners

Where it's running

• Dartmouth-Hitchcock Medical Center
  Lebanon, New Hampshire, United States Recruiting

Study contacts

• Principal investigator: Ryan E Little, MD — Dartmouth-Hitchcock Medical Center
• Study coordinator: Ryan E Little, MD
• Email: Ryan.E.Little@hitchcock.org
• Phone: (603) 650 8123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older

  This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07485543

• VX-272 dose escalation in healthy adults

  This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Tempe, Arizona · NCT07437105

• Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis

  This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07342920

• Dose escalation of VX-581 to check safety and drug levels in healthy adults

  The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Overland Park, Kansas · NCT07283770

• PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care

  This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.

  Recruiting CHU de Reims · Reims · NCT07274631

• Collecting sputum samples at home for cystic fibrosis patients

  This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.

  Recruiting at 4 sites University of Pennsylvania · Denver, Colorado and 3 other locations · NCT06950892

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.